COVID-19 Point-of-Care Diagnostics That Satisfy Global Target Product Profiles
COVID-19 pandemic will continue to pose a major public health threat until vaccination-mediated herd immunity is achieved. Most projections predict vaccines will reach a large subset of the population late in 2021 or early 2022. In the meantime, countries are exploring options to remove strict lockdown measures and allow society and the economy to return to normal function. One possibility is to expand on existing COVID-19 testing strategies by including large-scale rapid point-of-care diagnostic tests (POCTs). Currently, there is significant variability in performance and features of available POCTs, making selection and procurement of an appropriate test for specific use case difficult. In this review, we have used the World Health Organization’s (WHO) recently published target product profiles (TPPs) for specific use cases of COVID-19 diagnostic tests to screen for top-performing POCTs on the market. Several POCTs, based on clinical sensitivity/specificity, the limit of detection, and time to results, which meet WHO TPP criteria for direct detection of SARS-CoV-2 (acute infection) or indirect diagnosis of past infection (host antibodies), are highlighted here..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Diagnostics - 11(2021), 1, p 115 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdi Ghaffari [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.3390/diagnostics11010115 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ013302949 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ013302949 | ||
| 003 | DE-627 | ||
| 005 | 20240414080812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/diagnostics11010115 |2 doi | |
| 035 | |a (DE-627)DOAJ013302949 | ||
| 035 | |a (DE-599)DOAJ4c85a89906774db4ae83f4441c9f8892 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Abdi Ghaffari |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Point-of-Care Diagnostics That Satisfy Global Target Product Profiles |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a COVID-19 pandemic will continue to pose a major public health threat until vaccination-mediated herd immunity is achieved. Most projections predict vaccines will reach a large subset of the population late in 2021 or early 2022. In the meantime, countries are exploring options to remove strict lockdown measures and allow society and the economy to return to normal function. One possibility is to expand on existing COVID-19 testing strategies by including large-scale rapid point-of-care diagnostic tests (POCTs). Currently, there is significant variability in performance and features of available POCTs, making selection and procurement of an appropriate test for specific use case difficult. In this review, we have used the World Health Organization’s (WHO) recently published target product profiles (TPPs) for specific use cases of COVID-19 diagnostic tests to screen for top-performing POCTs on the market. Several POCTs, based on clinical sensitivity/specificity, the limit of detection, and time to results, which meet WHO TPP criteria for direct detection of SARS-CoV-2 (acute infection) or indirect diagnosis of past infection (host antibodies), are highlighted here. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a point-of-care diagnostic test | |
| 650 | 4 | |a target product profile | |
| 650 | 4 | |a clinical performance | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Robyn Meurant |e verfasserin |4 aut | |
| 700 | 0 | |a Ali Ardakani |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Diagnostics |d MDPI AG, 2012 |g 11(2021), 1, p 115 |w (DE-627)DOAJ000099708 |x 20754418 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:1, p 115 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/diagnostics11010115 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/4c85a89906774db4ae83f4441c9f8892 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2075-4418/11/1/115 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2075-4418 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 1, p 115 | ||